Dementia Research Centre, National Hospital for Neurology and Neurosurgery
Welcome,         Profile    Billing    Logout  
 5 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mummery, Catherine
DIAN-TU, NCT06384573: Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

Recruiting
3
65
Europe, US, RoW
lecanemab, BAN2401
Washington University School of Medicine, Alzheimer's Association, Eisai Inc.
Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
11/29
11/29
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
DIAN-TU-002, NCT06647498: A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Not yet recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug, LY3372993, Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
06/34
DIAN-TU, NCT05269394: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Active, not recruiting
2/3
197
Europe, Canada, Japan, US, RoW
E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc.
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001

Checkmark From DIAN-TU trial
Feb 2020 - Feb 2020: From DIAN-TU trial
Checkmark Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Feb 2020 - Feb 2020: Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Checkmark DIAN TU: N=210
More
Recruiting
2/3
490
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT05552157: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Not yet recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug (SC), Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
06/34
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Recruiting
2
282
Europe, Canada, US, RoW
GSK4527226, Placebo
GlaxoSmithKline, Alector Inc.
Alzheimer's Disease
12/26
05/29
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
NCT06297590: A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
1
32
Europe, Japan, US
LY3954068, Placebo, Flortaucipir F18
Eli Lilly and Company
Alzheimer Disease
02/27
02/27
NCT05551741: A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

Recruiting
1
40
Europe, RoW
IBC-Ab002, Placebo
Immunobrain Checkpoint, National Institute on Aging (NIA), Alzheimer's Association
Alzheimer's Disease
11/25
11/25
Silva, Miguel MF
NCT05551741: A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

Recruiting
1
40
Europe, RoW
IBC-Ab002, Placebo
Immunobrain Checkpoint, National Institute on Aging (NIA), Alzheimer's Association
Alzheimer's Disease
11/25
11/25
AMERICCAASS, NCT05295641: American Registry of Ambulatory or Acute Decompensated Heart Failure

Active, not recruiting
N/A
6679
US, RoW
Fundacion Clinica Valle del Lili, Sociedad Interamericana de Cardiología (SIAC), Consejo Interamericano de Falla Cardíaca e Hipertensión Pulmonar (CIFACAH)
Heart Failure
11/23
06/24
Ricamara, Marivic
STRIDES, NCT05490563: - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

Terminated
2/3
23
Europe, US, RoW
SLS-005, Placebo
Seelos Therapeutics, Inc.
Spinocerebellar Ataxia Type 3
11/23
11/23
NCT05551741: A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

Recruiting
1
40
Europe, RoW
IBC-Ab002, Placebo
Immunobrain Checkpoint, National Institute on Aging (NIA), Alzheimer's Association
Alzheimer's Disease
11/25
11/25

Download Options